Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.

Sci Rep · 2022 · PMC8776729 · PMID 35058539

Europe PMC DOI

hedged sentences

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

a significant trendP = 0.04actually significant

This analysis was possible only for DFS analysis for lack of sufficient data in OS population and confirmed a significant trend for reduced DFS benefit for adjuvant chemotherapy in low risk subgroup (P = 0.04).

also in 9,775 other papers

did not reach statistical significanceno p-value reported

Although a DFS difference between any adjuvant treatment and surgery was evident, it did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Our analysis provide a more expanded population of MSI CRC patients including also n = 31 randomized studies other than observational series (n = 2958), and showed a trend for better DFS with adjuvant chemotherapy in high-risk stage III CRCs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.